Purchase Order HHSN272201701016P

<p>This is a firm-fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Alpha Diagnostic International Inc., a woman-owned small business. The order is for the procurement of 12 bulk kits of the AMBIS # 1774444 Human Anti-Zaire Ebola Virus Glycoprotein (GP) IgG ELISA Kit, 96 tests quantitative. The total ceiling value of the award is $69,910.00, with a completion date of June 16, 2016. This award does not have a set-aside designation.</p>

This is a firm fixed price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Alpha Diagnostic International Inc., a minority-owned, woman-owned small business. The contract is for the provision of a Human Anti-Zaire Ebola Virus Nucleoprotein (NP) IgG ELISA Kit, a quantitative 96-test kit. The contract has a ceiling value of $7,501.00 and a period of performance ending on May 22, 2016. The contract was awarded on April 22, 2016...

This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services (HHS), to Alpha Diagnostic International Inc. The award, valued at $13,666.00, is for the procurement of an &quot;AMBIS #1709226 HUMAN ANTI-ZAIRE-EBOLA VIRUS GLYCOPROTEIN (GP) IGG ELISA KIT&quot;. This is a firm fixed-price purchase order with a completion date of November 14, 2014. The contract does not have a set-aside designation.

<p>This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Alpha Diagnostic International Inc. for the delivery of human anti-Zaire Ebola virus glycoprotein (GP) IgG ELISA kits and low NSB diluent. The contract has a ceiling value of $82,765.00 and a period of performance that ended on May 19, 2016. The contract does not have a set-aside designation.</p>

This $2,306,148 federal contract was awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Battelle Memorial Institute to support an efficacy study of a monoclonal antibody (MAb) therapeutic against the Ebola virus (EBOV) lethal challenge in rhesus macaques. The contract is a Delivery Order issued under Battelle's BARDA Biological Animal Model Development 2017-2022 Indefinite Delivery/Indefinite Quantity (IDIQ)...

This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Ridgeback Biotherapeutics LP, a for-profit, woman-owned business. The contract, valued at $13,988,547.00, is for Ridgeback Biotherapeutics' efforts related to the development of the monoclonal antibody (MAB) treatment MAB114 for Ebola. The contract does not have a set-aside designation and is a cost-no-fee arrangement. The period of...

This firm fixed-price purchase order contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Alpha Diagnostic International Inc. on September 2, 2015. The contract, valued at $11,255.00, is for the provision of an Antibody ELISA Kit and recombinant (HEK) Zaire Ebola products. The contract has a completion date of September 11, 2015 and does not utilize a set-aside designation. Alpha Diagnostic International Inc. is a minority-owned, woman-owned small...

This is a $10,495 firm fixed price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Alpha Diagnostic International Inc., a minority-owned, woman-owned small business. The contract is for the procurement of 20 units of the AMBIS # 1768645 Human Anti-Zaire-Ebola Virus Glycoprotein (GP) IgM ELISA Kit at a unit price of $516.00. The contract has a completion date of June 16, 2016 and was awarded on December 4, 2015. This contract does not have a...

This contract was awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $43,075,091.00 cost-plus-fixed-fee contract provides research, development, and production services to support studies and operations related to the Ebola virus and other emerging and re-emerging infectious diseases. Leidos Biomedical Research has served as a prime contractor and...

This is a $856,704,795.58 definitive cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in infectious disease treatments. The contract is for the procurement of therapeutics to address Ebola, Sudan, and Marburg viruses. There is no set-aside designation for this contract, which has an ultimate completion date of...